Ian Haydock's profile photo

Ian Haydock

Tokyo

Editor-in-Chief, Asia-Pacific at Scrip

Editor-in-Chief, Asia-Pacific at The Pink Sheet

Tokyo-based Editor-in-Chief, Asia-Pacific, for @PharmaScrip @PharmaPinkSheet, @citeline, @NorstellaCo. All views my own, RTs not endorsements.

Articles

  • 6 days ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma. Weekly audio roundup of selected content from Scrip's global team.

  • 1 week ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: Novo Nordisk’s CEO forced out; quantifying biopharma’s contribution to the US economy; a history of MASH deals; lift for AstraZeneca’s asthma ambitions; and major Japanese firms see US revenue growth. Weekly audio roundup of selected content from Scrip's global team

  • 2 weeks ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls. Weekly audio roundup of selected content from Scrip's global team

  • 3 weeks ago | insights.citeline.com | Ian Haydock

    Multiple Launches Help Lilly’s Japan Growth Building Alzheimer’s, Obesity Presence Lilly saw solid growth for its business in Japan last year on the back of several new launches and it building its obesity and Alzheimer's portfolios in the country. Growth For Lilly's Japan Operation Helped By Multiple Launches • Source: Shutterstock

  • 3 weeks ago | insights.citeline.com | Ian Haydock

    Quick Listen: Scrip’s Five Must-Know ThingsIn this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology. weekly audio roundup of selected content from Scrip's global team

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
982
Tweets
9K
DMs Open
No
No Tweets found.